DIRS.INFO top alerts submit data jurnalism about API
login
Top related persons:
MoonLake - 2 — CNBC's Michael Bloom - 2 It's - 1 MoonLake Immunotherapeutics - 1 Stifel - 1 Alex Thompson - 1 we've - 1 Thompson - 1
Top related locs:
Acelyrin Bengaluru Zug Switzerland New York
Top related orgs:
Thomson - 2 Evercore ISI - 1 Aclaris Therapeutics - 1 Gartner - 1 Clark - 1 Bristol Myers Squibb - 1 Ventyx Biosciences - 1 Apogee Therapeutics - 1

Search resuls for: "hidradenitis suppurativa"


6 mentions found


☆ Stifel says this under-the-radar biotech stock can still rally more than 50% from here
  + stars: | 2023-11-02 | by ( Lisa Kailai Han | ) www.cnbc.com   time to read: +1 min
It's not too late for investors to ride along with MoonLake Immunotherapeutics despite the Swiss biotech having more than quadrupled in price this year, according to Stifel. Shares of MoonLake have soared 354% in 2023, but Stifel believes more gains lay ahead. MLTX YTD mountain MLTX YTD chart Analyst Alex Thompson believes MoonLake's sonelokimab drug, which targets diseases in dermatology and rheumatology, could eventually achieve $4.2 billion in U.S. revenue. The next trial readout for the drug is in psoriatic arthritis, with data expected in early November. "We view recent acquisitions in the TYK2 and TL1A space ($4-11B) as supportive of Strategics' interest/willingness to pay premiums in these markets," Stifel noted.
Persons: It's, MoonLake Immunotherapeutics, Stifel, Alex Thompson, we've, Thompson, MoonLake, — CNBC's Michael Bloom
☆ Evercore ISI says this biotech stock is a high risk, high reward play, with more than 200% upside
  + stars: | 2023-10-03 | by ( Christina Cheddar Berk | ) www.cnbc.com   time to read: +2 min
Evercore ISI initiated coverage of Aclaris Therapeutics , a clinical stage biotech working on immunology and inflammation drugs, at an outperform, saying the market is underpricing its odds for success heading into the release of clinical trial data. Admittedly, the upcoming trial results may not be successful, which makes the bet a risky one, he said. If Aclaris is successful with zunsemetinib, it will be the only MK2 inhibitor on the market for rheumatoid arthritis, which Evercore ISI sees as an advantage. A similar drug from Bristol Myers Squibb wasn't successful in a different form of arthritis. Evercore ISI expects investors are only pricing in a 20% chance of positive data from the clinical trial, whereas the firm expects the odds are closer to 50%.
Persons: Gavin Clark, Clark, Gartner, zunsemetinib, Aclaris, Bristol Myers Squibb wasn't, — CNBC's Michael Bloom Organizations: Evercore ISI, Aclaris Therapeutics, Gartner, Clark, Bristol Myers Squibb
☆ Acelyrin's skin disease drug trial failure wipes off IPO gains
  + stars: | 2023-09-12 | by ( Christy Santhosh | ) www.reuters.com   time to read: +2 min
Sept 12 (Reuters) - Shares of drug developer Acelyrin (SLRN.O) on Tuesday erased all gains made since their stellar market debut in May, as the company's experimental lead drug failed to show superiority to placebo in reducing symptoms of an inflammatory skin disease. HS is a chronic inflammatory skin condition that causes painful lumps under the skin. Acelyrin said the trial was hit by early discontinuations as well as better placebo efficacy rates. However, Jefferies analyst Akash Tewari slashed the price target on Acelyrin's stock to $15 from $31, calling the latest data "painfully disappointing." "It's difficult to glean much from the data given how poorly the trial was run.
Persons: Acelyrin, Acelyrin's izokibep, Hidradenitis, Piper Sandler, Jefferies, Akash Tewari, We'll, Christy Santhosh, Saumyadeb Chakrabarty Organizations: Ventyx Biosciences, Apogee Therapeutics, Thomson Locations: Acelyrin, Bengaluru
☆ Exclusive: MoonLake Immunotherapeutics explores sale-sources
  + stars: | 2023-07-14 | by ( David Carnevali | ) www.reuters.com   time to read: +2 min
July 14 (Reuters) - MoonLake Immunotherapeutics (MLTX.O), a developer of an antibody-derived treatment for inflammatory skin conditions, is exploring a sale, according to people familiar with the matter. Immunology-focused companies have been coveted acquisition targets, as highlighted by recent deals such as Merck & Co's (MRK.N) $10.8 billion acquisition of Prometheus BioSciences Inc and Eli Lilly's (LLY.N) $2.4 billion purchase of Dice Therapeutics (DICE.O). MoonLake is testing Sonelokimab for the treatment of other inflammatory conditions, including psoriatic arthritis and psoriasis. If successful, MoonLake would encroach on a market dominated by bigger peers such as Novartis AG (NOVN.S) and AbbVie Inc (ABBV.N). In 2022, MoonLake went public through a merger with a special purpose acquisition company, which helped it raise more than $200 million in cash.
Persons: drugmakers, Eli Lilly's, MoonLake, hidradenitis suppurativa, hidradenitis, Merck KGaA, David Carnevali, Josie Kao Organizations: Nasdaq, Merck, Co's, Prometheus BioSciences, Dice Therapeutics, Novartis AG, AbbVie Inc, Citigroup, Thomson Locations: Zug, Switzerland, New York
☆ Aclaris shares tank as skin disorder drug fails mid-stage study
  + stars: | 2023-03-06 | by ( ) www.reuters.com   time to read: +1 min
Companies Aclaris Therapeutics Inc FollowMarch 6 (Reuters) - Aclaris Therapeutics Inc (ACRS.O) said on Monday its experimental drug failed to meet the main goal of a mid-stage study to treat a painful skin disorder, sending its shares tumbling more than 36% in premarket trading. The drug, zunsemetinib, did not meet the main goal of reducing abscesses in patients with moderate to severe hidradenitis suppurativa (HS) at week 12, compared with a placebo. HS is a chronic inflammatory skin condition that causes abscesses and scarring on the skin. The study also failed to meet its secondary goals, which included percentage of patients who achieved at least a 50% reduction in number of inflammatory lesions, Aclaris said. The drug is being tested to treat other inflammatory conditions such as rheumatoid arthritis and psoriatic arthritis, far bigger markets than HS.
☆ This under-the-radar stock can surge more than 60% on a possible treatment for immuno-inflammatory diseases, Goldman Sachs says
  + stars: | 2022-12-01 | by ( Sarah Min | ) www.cnbc.com   time to read: +2 min
Shares of Aclaris Therapeutics can surge more than 60% on the back of a possible new treatment for immuno-inflammatory diseases, including rheumatoid arthritis, according to Goldman Sachs. Analyst Corinne Jenkins initiated coverage of Aclaris Therapeutics with a buy rating, saying she expects promising results out of clinical trials for the company's drug called zunsemetinib . The biopharma stock has already outperformed this year, up nearly 5% in 2022, while the S & P 500 declined roughly 14%. The analyst expects that there will be further catalysts for positive upside as the Aclaris unveils further data for zunsemetinib in 2023. "We see this profile as sufficient to garner modest share in these large indications, fostering a sizable peak sales opportunity which we estimate at > $5B across indications," Jenkins wrote.
0 next >>
Total: 6